Stock 000403 PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Pacific Shuanglin Bio-pharmacy Co., LTD

Equities

000403

CNE000000F14

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
26.7 CNY -0.34% Intraday chart for Pacific Shuanglin Bio-pharmacy Co., LTD -2.23% -1.98%
May. 23 Pacific Shuanglin Bio-pharmacy's Unit Gets Nod to Trial Intravenous Human Immunoglobulin MT
May. 09 Pacific Shuanglin Bio-pharmacy Subsidiary Gets Plasmapheresis License MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pacific Shuanglin Bio-pharmacy's Unit Gets Nod to Trial Intravenous Human Immunoglobulin
MT
Pacific Shuanglin Bio-pharmacy Co., LTD Approves Cash Dividend for the Year 2023
CI
Pacific Shuanglin Bio-pharmacy Subsidiary Gets Plasmapheresis License
MT
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Pacific Shuanglin Bio-pharmacy's 2023 Profit Jumps 4% Despite Lower Revenue; Shares Rise 4%
MT
Pacific Shuanglin Bio-pharmacy's Profit Seen More Than Doubling in Q1; Shares Up 3%
MT
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Pacific Shuanglin Bio-pharmacy Co., LTD announced a financing transaction
CI
Pacific Shuanglin Bio-pharmacy Unit Gets Nod to Trial Human Coagulation Factor IX
MT
Pacific Shuanglin Bio-pharmacy Co., LTD Approves Board Appointments
CI
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Pacific Shuanglin Bio-pharmacy Obtains Another Blood Collection License
MT
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Pacific Shuanglin Bio-pharmacy Obtains Blood Plasma Collection License
MT
Tranche Update on Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback Plan announced on September 1, 2022.
CI
Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback announced on September 1, 2022 has expired with 1,968,378 shares, representing 0.27% for CNY 40.1 million.
CI
Pacific Shuanglin Bio-Pharmacy Co., Ltd Announces Final Dividend Implementation on A Shares for the Year 2022, Payable on July 20, 2023
CI
Tranche Update on Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback Plan announced on September 1, 2022.
CI
Pacific Shuanglin Bio-pharmacy's Unit Gets Permit to Operate Two Plasma Hubs
MT
Pacific Shuanglin Bio-Pharmacy Co., Ltd Approves 2022 Profit Distribution Plan
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 000403 Stock
  4. News Pacific Shuanglin Bio-pharmacy Co., LTD